Journal of Urologic Oncology

Search

Page Path

Kidney Cancer

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study: Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park; Journal of Urologic Oncology. 2024;22(1):59-67. Published online March 31, 2024; DOI: https://doi.org/10.22465/juo.234600660033
Cited By 1; Full text PubReader ePub PDF

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

MOST READ MOST CITED

5,263	New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
4,829	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
4,202	The Present and Future of Intravesical Therapy in Bladder Cancer
3,980	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
3,929	Complex Epidemiology of Prostate Cancer in Asian Countries

Cited By 6	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 4	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Cited By 3	The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Cited By 2	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use

Editorial Office: Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817, FAX: +82-2-742-4665 Email: journal@e-juo.org

Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: kspe.editor@gmail.com